In a phase I study, combination HDACi abexinostat with pazopanib in patient of RCC with tumor progression after received an average 2.5 lines of prior therapy and 1.6 lines of prior VEGF-targeting treatment received 27% of objective response rate and average 10.5 months of response duration (Aggarwal et al., 2017). This evidence concerns the gene VEGFA and renal cell adenocarcinoma.